2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1000

Pathogenic Role of CXC Chemokine receptor 3-Positive B Cells in Bone Destruction of Rheumatoid Arthritis
Abstract Number: 1255

Pathogenic Role of Tyrosyl–Transfer RNA Synthetase in Anti-Synthetase Syndrome
Abstract Number: 498

Patient Experience with Initiation of SQ and Oral MTX
Abstract Number: 2033

Patient Factors Associated with Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Abstract Number: 1380

Patient Global Impression of Change for Patient Reported Outcomes in Rheumatoid Arthritis: Impact of Comorbidities
Abstract Number: 1287

Patient Perspective of the Main Health Concerns and Needs of Living with Hand Osteoarthritis
Abstract Number: 1507

Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada
Abstract Number: 2768

Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone
Abstract Number: 108

Patient Reported Outcomes Following Total Knee Arthroplasty in Rheumatoid Arthritis and Osteoarthritis
Abstract Number: 106

Patient Reported Outcomes Following Upper Extremity Arthroplasties in RA -a Report from the Swedish National Register of Rheuma Surgery (RAKIR)
Abstract Number: 2967

Patient Reported Pain By the Paindetect Questionnaire Reveals Multimodal Elements to Pain Perception in Rheumatoid Arthritis
Abstract Number: 2421

Patient Treatment Goals in Rheumatoid Arthritis: Results of Focus Groups Among Rheumatologists, English and Spanish-Speaking Patients
Abstract Number: 428

Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis
Abstract Number: 300

Patient-Reported Joint Count in Juvenile Idiopathic Arthritis: The Reliability of a Mannequin Format
Abstract Number: 2486

Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].